Director Rita Jain joins First Tracks Biotherapeutics (TRAXV) as reporting insider

Rhea-AI Filing Summary

First Tracks Biotherapeutics, Inc. director Rita Jain filed an initial Form 3, formally registering as an insider of the company. The filing reports no transactions, no derivative activity, and no specific share holdings at this time.

Key Terms

Form 3, reporting insider, derivative securities

3 terms

Form 3 regulatory

"filed an initial Form 3, formally registering as an insider"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting insider regulatory

"joins First Tracks Biotherapeutics (TRAXV) as reporting insider"

derivative securities financial

"No derivative securities are reported for Rita Jain in this Form 3"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Rita Jain	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Rita Jain's Form 3 mean for First Tracks Biotherapeutics (TRAXV)?

Rita Jain’s Form 3 formally identifies her as a director and insider of First Tracks Biotherapeutics. The filing reports no share transactions or derivative positions, serving only as an initial statement of insider status with the SEC.

Did Rita Jain buy or sell any First Tracks Biotherapeutics (TRAXV) shares in this Form 3?

No, the Form 3 shows no reported purchases or sales of First Tracks Biotherapeutics shares. The transaction summary lists zero buy, sell, exercise, gift, tax-withholding, or restructuring events, indicating this is purely an initial registration.

Does the Form 3 show how many TRAXV shares Rita Jain owns?

No, this Form 3 does not disclose any specific share holdings for Rita Jain. The filing’s transaction and holding summaries are all zero, so it functions only as an initial insider identification without position details.

Are there any derivative securities reported for Rita Jain in TRAXV?

No derivative securities are reported for Rita Jain in this Form 3. The derivative summary is empty and the transaction summary shows zero derivative transactions or exercises, indicating no options or similar instruments are listed.

Does the Form 3 for First Tracks Biotherapeutics mention a Rule 10b5-1 trading plan?

No, the filing’s footnote section does not describe any Rule 10b5-1 trading plan. With no transactions or derivative positions reported, the document contains only basic insider-identification details for director Rita Jain.